PRNewsWire
31 May 2026, 21:36 UTC · 5h ago
Source · https://www.prnewswire.com/news-releases/servier-to-present-extended-follow-up-results-from-the-phase-3-indigo-trial-showing-durable-and-sustained-treatment-benefits-of-voranigo-vorasidenib-at-asco-2026-302786471.html
Read source
Search tags
Story key points
3 claims · impact-rated
Extended follow-up results from the Phase 3 INDIGO trial show that VORANIGO (vorasidenib) provides durable and sustained treatment benefits for patients with Grade 2 IDH-mutant glioma over more than three years. — Long-term efficacy data for a targeted therapy in a difficult-to-treat cancer increases the drug's commercial potential and clinical adoption.
+0.60Data indicate that clinical benefits of VORANIGO continue to improve over time and delay disease progression. — Improving responses over time suggests a superior therapeutic profile compared to the historical 'watch and wait' strategy.
+0.40The extended analysis included 21.3 months of additional unblinded data with a median follow-up of 41.6 months. — Provides statistical robustness to the efficacy claims, though it is a supporting detail rather than a new commercial catalyst.
+0.20Ticker attribution
Continue reading
6 related stories
Model heads
No ticker sentiment head found.
No ticker relationship head found.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
2h ago
